- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.54 License Development and Supply Agreement
- 10.55 Stock Purchase Agreement
- 10.57 Form of Common Stock and Warrant Purchase Agreement
- 10.58 Form of Investors Rights Agreement
- 10.59 Form of Common Stock Purchase Warrant
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO and CFO Certification
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Antares Pharma, Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-20389, 333-40483, 333-64480, 333-111177) on Form S-8, registration statements (Nos. 333-61950, 333-96739, 333-103958) on Form S-3 and registration statement (No. 333-109114) on Form S-2 of Antares Pharma, Inc. (formerly known as Medi-Ject Corporation) of our reports dated March 10, 2006, with respect to the consolidated balance sheets of Antares Pharma, Inc. and subsidiaries as of December 31, 2005 and 2004, and the related consolidated statements of operations, stockholders’ equity and comprehensive loss, and cash flows for each of the years in the three-year period ended December 31, 2005, and the related financial statement schedule, which reports appear in the December 31, 2005 annual report on Form 10-K of Antares Pharma, Inc.
/s/ KPMG LLP
Minneapolis, Minnesota
March 15, 2006